You are here:

  1. Home
  2. NICE Guidance
  3. NICE Advice
  4. Evidence summaries

Pouchitis: rifaximin

  • Evidence summary
  • Reference number: ESUOM30
  • Published:  25 March 2014
  • Advice
  • Information for the public
Download (PDF)
  • Key points from the evidence
  • Overview for healthcare professionals
  • Relevance to NICE guidance programmes
  • Intervention and alternatives
  • Evidence review: efficacy
  • Evidence review: safety
  • Evidence review: economic issues
  • Evidence strengths and limitations
  • Summary for patients
  • References
  • Development of this evidence summary
  • Appendix: Search strategy and evidence selection
  • About 'Evidence summaries: unlicensed or off-label medicines'

Relevance to NICE guidance programmes

This use of rifaximin is not appropriate for referral for a NICE technology appraisal and is not currently planned into any other work programme.

NICE has issued clinical guidelines on conditions that may be associated with surgical construction of an ileoanal pouch:

  • Ulcerative colitis: management in adults, children and young people (NICE clinical guideline 166)

  • Colorectal cancer: the diagnosis and management of colorectal cancer (NICE clinical guideline 131).

NICE guidance is in development for a licensed indication for rifaximin:

  • Rifaximin for the maintenance treatment of hepatic encephalopathy (NICE technology appraisal guidance, publication date to be confirmed).


Next page Intervention and alternatives Previous page Overview for healthcare professionals
Back to top